125 related articles for article (PubMed ID: 31856850)
1. Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials.
Shaunfield S; Jensen S; Fisher AP; Webster K; Shahabi S; Ganguli A; Cella D
Health Qual Life Outcomes; 2019 Dec; 17(1):185. PubMed ID: 31856850
[TBL] [Abstract][Full Text] [Related]
2. Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18).
Jensen SE; Kaiser K; Lacson L; Schink J; Cella D
Gynecol Oncol; 2015 Feb; 136(2):317-22. PubMed ID: 25499602
[TBL] [Abstract][Full Text] [Related]
3. A new index of priority symptoms in advanced ovarian cancer.
Jensen SE; Rosenbloom SK; Beaumont JL; Abernethy A; Jacobsen PB; Syrjala K; Cella D
Gynecol Oncol; 2011 Feb; 120(2):214-9. PubMed ID: 21075440
[TBL] [Abstract][Full Text] [Related]
4. Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Trigg A; Kelly M; Iadeluca L; Chang J; Moreno-Koehler A; Yaworsky A; Krohe M; Rider A; Cappelleri JC; Cella D; Cocks K
Future Oncol; 2021 Oct; 17(30):3951-3964. PubMed ID: 34287020
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Lee M; Lee Y; Kim K; Park EY; Lim MC; Kim JS; Kim HS; Kim YB; Kim YM; Joo J; Park SY; Choi CH; Kim JH
Cancer Res Treat; 2019 Jan; 51(1):112-118. PubMed ID: 29510610
[TBL] [Abstract][Full Text] [Related]
6. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
von Gruenigen VE; Huang HQ; Cella D; Zevon M; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; Wenzel L
Gynecol Oncol; 2018 Jul; 150(1):119-126. PubMed ID: 29778506
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Wenzel L; Huang HQ; Cella D; McKinney CO; Zevon MA; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; von Gruenigen VE
Gynecol Oncol; 2021 Nov; 163(2):392-397. PubMed ID: 34548162
[TBL] [Abstract][Full Text] [Related]
8. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
Rothrock NE; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Cella D
Value Health; 2013; 16(5):789-96. PubMed ID: 23947972
[TBL] [Abstract][Full Text] [Related]
9. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
10. "Lower abdominal pains, as if I was being squeezed…in a clamp": A Qualitative Analysis of Symptoms, Patient-Perceived Side Effects and Impacts of Ovarian Cancer.
Martin ML; Halling K; Eek D; Reaney M
Patient; 2020 Apr; 13(2):189-200. PubMed ID: 31691205
[TBL] [Abstract][Full Text] [Related]
11. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
12. Individuals with knee impairments identify items in need of clarification in the Patient Reported Outcomes Measurement Information System (PROMIS®) pain interference and physical function item banks - a qualitative study.
Lynch AD; Dodds NE; Yu L; Pilkonis PA; Irrgang JJ
Health Qual Life Outcomes; 2016 May; 14():77. PubMed ID: 27169858
[TBL] [Abstract][Full Text] [Related]
13. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.
Sailors MH; Bodurka DC; Gning I; Ramondetta LM; Williams LA; Mendoza TR; Agarwal S; Sun CC; Cleeland CS
Gynecol Oncol; 2013 Aug; 130(2):323-8. PubMed ID: 23685012
[TBL] [Abstract][Full Text] [Related]
14. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.
Pearman TP; Beaumont JL; Mroczek D; O'Connor M; Cella D
Cancer; 2018 Mar; 124(5):991-997. PubMed ID: 29131323
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
16. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
[TBL] [Abstract][Full Text] [Related]
17. Reliability and validity of the functional assessment of cancer therapy-ovarian.
Basen-Engquist K; Bodurka-Bevers D; Fitzgerald MA; Webster K; Cella D; Hu S; Gershenson DM
J Clin Oncol; 2001 Mar; 19(6):1809-17. PubMed ID: 11251013
[TBL] [Abstract][Full Text] [Related]
18. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
Armstrong TS; Gning I; Mendoza TR; Vera-Bolanos E; Gilbert MR; Rhines LD; Weinberg JS; Sanchez-Williams G; Levin V; Burton AW; Cleeland C
J Neurosurg Spine; 2010 Apr; 12(4):421-30. PubMed ID: 20367379
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms.
Donovan HS; Ward S; Sherwood P; Serlin RC
J Pain Symptom Manage; 2008 Mar; 35(3):242-57. PubMed ID: 18201866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
